Israeli Biotech Firm Uses Blue River Crabs to Revolutionize Bone Healing for Wounded Soldiers

Amorphecal, an Israeli biotech company founded in 2015 in the Arava region, has developed a groundbreaking calcium carbonate supplement inspired by the blue river crab's unique ability to rapidly shed and rebuild its skeleton. Founder Yossi Ben's fascination with these crabs led to the discovery of an amorphous calcium capsule that enables fast bone regeneration, a mechanism now replicated in their medical products.

The company’s breakthrough gained critical attention during the October 7 war, when CEO Eden Ben, a biomedical engineer and son of the founder, was called for reserve duty and witnessed severe soldier injuries firsthand. Motivated by the urgent need, Amorphecal provided their amorphous calcium supplements free to hospitals treating wounded soldiers, resulting in remarkable recoveries, including cases where soldiers with previously non-healing fractures regained mobility.

Clinical and preclinical studies confirm that the supplement can halve bone healing time, offering hope not only to injured soldiers but also to elderly patients suffering from osteoporosis and dangerous fractures. The product’s superior absorption is due to its nanometric amorphous calcium carbonate structure, which the body assimilates more efficiently than traditional crystalline calcium.

The company overcame significant challenges in mass-producing the unstable amorphous calcium form, a feat achieved with the help of Dr. Yigal Blum, an Israeli-American nanotechnology expert. Amorphecal now holds 193 patents worldwide and is pursuing FDA approval to become a leading global biotech firm.

Patient testimonials, such as 74-year-old Hanna Arviv who reversed years of bone deterioration and pain, underscore the supplement’s impact. Amorphecal’s commitment to developing industry and employment in the Arava region reflects its Zionist vision, with plans to expand production both in Israel and internationally. CEO Eden Ben emphasizes their focus on clinical validation and safety, aiming for a Nasdaq IPO in the near future.